Mouse IL-7 ELISA kit
- Known as:
- Mouse Interleukin-7 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- lf-ek50655
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Mouse IL-7 ELISA kit
Related genes to: Mouse IL-7 ELISA kit
- Gene:
- IL7 NIH gene
- Name:
- interleukin 7
- Previous symbol:
- -
- Synonyms:
- IL-7
- Chromosome:
- 8q21.13
- Locus Type:
- gene with protein product
- Date approved:
- 1989-10-12
- Date modifiied:
- 2016-10-11
- Gene:
- IL7R NIH gene
- Name:
- interleukin 7 receptor
- Previous symbol:
- -
- Synonyms:
- CD127, IL7RA
- Chromosome:
- 5p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2019-04-23
Related products to: Mouse IL-7 ELISA kit
Related articles to: Mouse IL-7 ELISA kit
- Delayed immune recovery after hematopoietic stem cell (HSC) transplantation is associated with a poor clinical outcome. We study the role of unfolded protein response (ER stress) in hematopoietic regeneration within the bone marrow (BM) microenvironment. We reveal that BM endothelium PERK activation is a prominent feature of patients with leukemia and is a hallmark response in mice following ionizing irradiation. Ablating endothelial Perk boosts NOTCH ligand DLL4 expression and promotes DLL4-dependent early HSC and B progenitor regeneration. Single-cell analysis reveals that endothelial DLL4 activates NOTCH3 expressed by mesenchymal stroma cells, and that the PERK-DLL4 axis coordinates the regulation of lymphoid commitment. NOTCH3 is critical for the upregulation of IL7 following irradiation and the expansion of lymphoid progenitors. These findings not only unveil an ER stress-controlled vascular-stroma signaling mechanism in regenerative hematopoiesis but also highlight PERK blockade as a promising strategy to improve immune recovery after myeloablative transplantation. - Source: PubMed
Publication date: 2026/09/10
Zou BingqingChen QiuyunZheng JunjunMa YiminMyers JayShang YinghuiHuang MofeiChristensen PaulAdoro StanleyTang Chih-Hang AnthonyHu Chih-Chi AndrewKiran Pingali Sai RaviXin WeiChan Keith SysonWong StephenZu YouliJafar-Nejad HamedZhou Lan - Gastric cancer is the fifth most common cancer worldwide and the fifth leading cause of cancer-related death. Its poor prognosis is primarily due to a late diagnosis and a lack of effective treatments for advanced disease. - Source: PubMed
Publication date: 2026/09/09
Brodkin JefimKaprio TuomasMustonen HarriLeppä AlliKokkola ArtoSalmi MarkoJalkanen SirpaHaglund CajBöckelman Camilla - The thymus, as a vital immune organ in the human body, provides the essential microenvironment for the development, differentiation, and maturation of T lymphocytes. With advancing age, the thymus gradually undergoes atrophy and degeneration, primarily characterized by structural disruption of thymic epithelial cells, leading to slowed T cell development and reduced output. Experimental studies have identified multiple regenerative pathways, including IL-7, KGF, BMP4, IL-22, RANKL, regulatory T cells, FOXN1-directed approaches, and sex-steroid blockade. Recent human observational studies also associate preserved thymic health with lower disease risk and better outcomes after cancer immunotherapy. However, most regenerative interventions remain preclinical, and no thymus-directed strategy has yet been shown to improve cancer immunotherapy outcomes in a randomized clinical trial. This review summarizes mechanisms of thymic involution and injury, evaluates regenerative strategies according to evidence level, and discusses the opportunities, limitations, and safety considerations for translating thymic regeneration into cancer care. - Source: PubMed
Publication date: 2026/08/25
Chen ZengkuanWang QiLu QiqiLiu WeiweiWu Xianguo - Cytokines used during chimeric antigen receptor (CAR) T-cell manufacturing can influence product differentiation and functional fitness. - Source: PubMed
Publication date: 2026/08/25
Val-Casals MariaAltuna AnePérez-Amill LorenaArmand-Ugón MercedesPeña SergioLópez-Pecino AnaColomer DolorsEsteve JordiJuan ManelKlein-González Nela - Chimeric antigen receptor (CAR) T-cell therapies have shown limited promise in solid tumors owing to the immunosuppressive tumor microenvironment. TAK-102 is a next-generation, glypican-3 (GPC3)-targeted CAR T-cell therapy engineered to co-express interleukin-7 (IL-7) and chemokine ligand 19 (CCL19), enhancing T-cell survival and trafficking. In this first-in-human, open-label, phase 1, dose-escalation study (ClinicalTrials.gov: NCT04405778), we evaluated a single TAK-102 infusion in 11 patients with GPC3+ advanced solid tumors refractory or intolerant to standard therapies. Patients received TAK-102 at one of three dose levels following leukapheresis and lymphodepletion chemotherapy. The primary endpoints were the incidences of dose-limiting toxicities, treatment-emergent adverse events, and adverse events of special interest. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were hematologic, including neutropenia and leukopenia (81.8%), and cytokine release syndrome (54.5%), all grade 1-2. No objective responses were observed; however, five patients achieved stable disease (disease control rate, 45.5%). One patient had a 26.1% reduction in tumor size lasting 9 months, accompanied by a 51.6% decline in serum alpha-fetoprotein. Cellular kinetics showed dose-dependent expansion, with the highest exposure at 5 × 10⁸ CAR+ cells/body. Post-treatment biopsies revealed increased CD8+ T-cell infiltration and activation markers, although CAR+ cells were undetectable in tumor tissue. Serum CCL19 levels increased with dose, suggesting immune priming. These findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors. Further studies are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts. - Source: PubMed
Publication date: 2026/09/08
Kuboki YasutoshiKoyama TakafumiIkeda MasafumiSatake TomoyukiSawada TakeshiShimazu YutakaKondo ShunsukeKatsuya YukiKagehara HideakiAkaike TakenoriSingh AmanAtkuri KondalaPop-Damkov PetarTamada KojiNakajima Takako Eguchi